CD80 (B7-1): Function & Role in the Immune System
CD80 (also known as B7-1) is a cell surface protein on immune cells that plays a key role in T-lymphocyte activation and serves as a central regulator of adaptive immunity.
Things worth knowing about "CD80"
CD80 (also known as B7-1) is a cell surface protein on immune cells that plays a key role in T-lymphocyte activation and serves as a central regulator of adaptive immunity.
What is CD80?
CD80, also referred to as B7-1, is a type I transmembrane protein belonging to the immunoglobulin superfamily. It is primarily expressed on the surface of antigen-presenting cells (APCs), including dendritic cells, macrophages, and activated B-lymphocytes. CD80 functions as a critical co-stimulatory ligand that regulates the adaptive immune response.
Biological Function and Mechanism of Action
CD80 interacts with two distinct receptors on T-cells: CD28 and CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4). These interactions exert opposing effects on T-cell activity:
- CD80 – CD28 interaction: This binding provides the essential co-stimulatory signal required for full T-lymphocyte activation. Without this signal, T-cells may enter a state of anergy (functional inactivity) even when an antigen is recognized via the T-cell receptor.
- CD80 – CTLA-4 interaction: CTLA-4 binds CD80 with higher affinity than CD28 and delivers inhibitory signals that dampen T-cell activity. This mechanism is crucial for maintaining immunological self-tolerance and preventing excessive immune responses.
Clinical Significance
Autoimmune Diseases
Dysregulated CD80 expression or impaired CD80-mediated signaling can contribute to autoimmunity. Altered B7 co-stimulation has been observed in conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis. The drug abatacept (CTLA-4-Ig) exploits the CD80/CD86-CTLA-4 pathway to selectively inhibit excessive T-cell activation and is approved for the treatment of rheumatoid arthritis.
Oncology and Tumor Immunology
CD80 plays an increasingly important role in cancer immunotherapy. Tumors can downregulate CD80 expression to evade immune recognition. Conversely, artificially upregulating CD80 on tumor cells is being investigated as a strategy to elicit stronger anti-tumor immune responses. Immune checkpoint inhibitors targeting the CTLA-4 pathway (e.g., ipilimumab) indirectly enhance CD80-mediated T-cell activation.
Transplant Medicine
CD80-mediated co-stimulation is also relevant in the context of organ transplantation. Blockade of the CD80/CD86-CD28 pathway can reduce graft rejection and is employed as an immunosuppressive strategy.
CD80 as a Therapeutic Target
Due to its central role in immune regulation, CD80 is an important therapeutic target. Biologics targeting the CD80/CD86 co-stimulation pathway are already clinically established or under clinical development:
- Abatacept (Orencia): A fusion protein combining CTLA-4 with the Fc region of an antibody, blocking CD80 and CD86. It is approved for the treatment of rheumatoid arthritis.
- Belatacept: A similar fusion protein used to prevent graft rejection following kidney transplantation.
References
- Sharpe, A.H. & Freeman, G.J. (2002). The B7-CD28 superfamily. Nature Reviews Immunology, 2(2), 116–126. https://doi.org/10.1038/nri727
- Linsley, P.S. & Ledbetter, J.A. (1993). The role of the CD28 receptor during T cell responses to antigen. Annual Review of Immunology, 11, 191–212.
- Frauwirth, K.A. & Thompson, C.B. (2002). Activation and inhibition of lymphocytes by costimulation. Journal of Clinical Investigation, 109(3), 295–299.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.